SG11202008247WA - Matrix metalloproteinase-1 antisense oligonucleotides - Google Patents

Matrix metalloproteinase-1 antisense oligonucleotides

Info

Publication number
SG11202008247WA
SG11202008247WA SG11202008247WA SG11202008247WA SG11202008247WA SG 11202008247W A SG11202008247W A SG 11202008247WA SG 11202008247W A SG11202008247W A SG 11202008247WA SG 11202008247W A SG11202008247W A SG 11202008247WA SG 11202008247W A SG11202008247W A SG 11202008247WA
Authority
SG
Singapore
Prior art keywords
antisense oligonucleotides
matrix metalloproteinase
metalloproteinase
matrix
antisense
Prior art date
Application number
SG11202008247WA
Inventor
Seon-Young Han
Kiho Sung
Myunghyo Hong
Youree Oh
Jeong-Seok Heo
Kang Won Jang
Original Assignee
Olipass Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olipass Corp filed Critical Olipass Corp
Publication of SG11202008247WA publication Critical patent/SG11202008247WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
SG11202008247WA 2018-05-18 2019-05-03 Matrix metalloproteinase-1 antisense oligonucleotides SG11202008247WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180057352 2018-05-18
PCT/KR2019/005994 WO2019221570A1 (en) 2018-05-18 2019-05-03 Matrix metalloproteinase-1 antisense oligonucleotides

Publications (1)

Publication Number Publication Date
SG11202008247WA true SG11202008247WA (en) 2020-12-30

Family

ID=68540475

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202008247WA SG11202008247WA (en) 2018-05-18 2019-05-03 Matrix metalloproteinase-1 antisense oligonucleotides

Country Status (13)

Country Link
US (1) US20210292369A1 (en)
EP (1) EP3794124A4 (en)
JP (1) JP7422406B2 (en)
KR (1) KR102194594B1 (en)
CN (1) CN112041447B (en)
AR (1) AR114533A1 (en)
AU (1) AU2019268955A1 (en)
BR (1) BR112020017892A2 (en)
CA (1) CA3091911A1 (en)
MX (1) MX2020009836A (en)
SG (1) SG11202008247WA (en)
TW (1) TWI832851B (en)
WO (1) WO2019221570A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102304280B1 (en) 2018-08-14 2021-09-23 올리패스 주식회사 Acetyl-CoA Carboxylase2 Antisense Oligonucleotides

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719262A (en) * 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US6617422B1 (en) * 1997-05-23 2003-09-09 Peter Nielsen Peptide nucleic acid monomers and oligomers
US20030105044A1 (en) * 2001-10-17 2003-06-05 Isis Pharmaceuticals Inc. Antisense modulation of matrix metalloproteinase 1 expression
US20040241651A1 (en) * 2000-04-07 2004-12-02 Alexander Olek Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations
DE10238298A1 (en) * 2002-08-21 2004-03-04 Beiersdorf Ag Use of antisense oligonucleotides for the treatment of degenerative skin symptoms
NZ546521A (en) * 2003-09-29 2009-09-25 Topigen Pharma Inc Oligonucleotide compositions and methods for treating disease including inflammatory conditions
WO2006088483A2 (en) * 2004-06-16 2006-08-24 Trustees Of Dartmouth College Compositions and methods for inhibiting the synthesis or expression of mmp-1
KR20090098710A (en) 2008-03-14 2009-09-17 주식회사 씨티아이바이오 Peptide nucleic acid derivatives with good cell penetration and affinity for nucleic acid
KR20120073536A (en) * 2010-12-27 2012-07-05 주식회사 파나진 Peptide nucleic acid having multi-charge
US20150240239A1 (en) * 2014-02-27 2015-08-27 Nugen Biosience (Taiwan) Co., Ltd. Methods and pharmaceutical compositions for inhibiting matrix metalloproteinases 1 by interference ribonucleic acid
US10900039B2 (en) * 2014-09-05 2021-01-26 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
AU2017309347B2 (en) * 2016-08-08 2020-11-19 Olipass Corporation Androgen receptor antisense oligonucleotides
US20190218255A1 (en) * 2016-09-16 2019-07-18 Olipass Corporation Scn9a antisense oligonucleotides
EP3526239B1 (en) * 2016-10-11 2021-11-03 Olipass Corporation Hif 1-alpha antisense oligonucleotides
JP7305542B2 (en) 2016-12-30 2023-07-10 オリパス コーポレーション Exon skipping by peptide nucleic acid derivatives

Also Published As

Publication number Publication date
AU2019268955A1 (en) 2020-11-26
TWI832851B (en) 2024-02-21
WO2019221570A1 (en) 2019-11-21
AR114533A1 (en) 2020-09-16
KR20190132220A (en) 2019-11-27
JP7422406B2 (en) 2024-01-26
JP2021524236A (en) 2021-09-13
CA3091911A1 (en) 2019-11-21
CN112041447A (en) 2020-12-04
EP3794124A4 (en) 2022-08-10
KR102194594B1 (en) 2020-12-23
TW202002991A (en) 2020-01-16
EP3794124A1 (en) 2021-03-24
MX2020009836A (en) 2021-01-08
CN112041447B (en) 2024-09-13
US20210292369A1 (en) 2021-09-23
BR112020017892A2 (en) 2020-12-22

Similar Documents

Publication Publication Date Title
IL276549A (en) Camk2d antisense oligonucleotides and uses thereof
IL268422A (en) Targeted oligonucleotides
GB201904709D0 (en) Chemically modified oligonucleotides
IL281834A (en) Nuclease-based rna depletion
GB201711809D0 (en) Antisense oligonucleotide
IL257091B (en) Targeted oligonucleotides
IL280724A (en) Chemically modified oligonucleotides targeting snps
IL275950A (en) Alpha-synuclein antisense oligonucleotides and uses thereof
IL277921A (en) Novel small activating rna
IL280581A (en) Variant rnai against alpha-synuclein
IL275903A (en) Antisense oligonucleotides targeting alpha-synuclein and uses thereof
SG10201913477UA (en) G-quadruplex-containing antisense oligonucleotides
IL275902A (en) Antisense oligonucleotides targeting alpha-synuclein and uses thereof
ZA202100244B (en) Combinatorial gene therapy
EP3999523A4 (en) Melanophilin antisense oligonucleotides
EP3532617A4 (en) Antisense oligonucleotides
SG10202008771WA (en) Combination therapy with liposomal antisense oligonucleotides
SG11202008247WA (en) Matrix metalloproteinase-1 antisense oligonucleotides
IL309445A (en) Pikfyve antisense oligonucleotides
IL263852B (en) Oligonucleotides comprising modified nucleosides
IL286826A (en) Angptl2 antisense oligonucleotides and uses thereof
SG11202012829RA (en) Acetyl-coa carboxylase2 antisense oligonucleotides
GB201714330D0 (en) Oligonucleotides
EP3565825A4 (en) Snap25 antisense oligonucleotides
GB201814450D0 (en) Antisense oligonucleotides